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ABSTRACT
The aim of this article is to review current literature on the response of soluble
interleukin-6 receptor to exercise and identify a potential role for sIL-6R in skele-
tal muscle function. We also provide novel data on the impact of eccentric exerci-
se on circulating levels. The aim of the research study was to investigate changes
in plasma concentration of soluble interleukin-6 receptor (sIL-6R) and soluble
glycoprotein 130 (sgp130) during recovery from exercise-induced muscle damage
(EIMD) up to 72 h and their relationship with delayed onset muscle soreness
(DOMS) and muscle function. 18 participants attended the laboratory on 4 cons-
ecutive days. On the first day, participants completed 6 sets of 10 repetitions of
unilateral eccentric-concentric knee flexions at a test speed of 1.05 rad.s-1 using a
Cybex Isokentic dynamometer to induce muscle damage of the hamstrings. Prior
to the eccentric exercise bout and each subsequent morning, following an over-
night fast, participants had a venous blood sample taken which was centrifuged
immediately and plasma frozen at -80°C until later analysis. Plasma IL-6 and
sgp130 were unchanged at any time point during recovery but sIL-6R was signifi-
cantly reduced at 48 h and 72 h post-exercise (p<0.05). Plasma sIL-6R was nega-
tively correlated with DOMS at 48 h post EIMD (r = 0 .45, p<0.05) and peak
muscle torque at 24 h and 48 h following EIMD (r = -.42; p<0.05; r = -.57;
p<0.01 respectively). Our novel finding that sIL-6R concentrations are decreased
2 - 3 days following a single bout of EIMD which may reflect a regulatory mecha-
nism controlling the influx of different leukocyte subpopulations into damaged tis-
sue, although this needs to be confirmed by future studies. Our data suggests an
association between sIL-6R, perception of pain and reduced peak muscle perfor-
mance post-EIMD but further investigation is warranted to explore this relations-
hip and implications for exercise performance.
Key Words: Interleukin-6, soluble interleukin-6 receptor, glycoprotein 130,
DOMS, eccentric exercise
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INTRODUCTION
Background to sIL-6R
Interleukin-6 (IL-6) is a multi-functional cytokine with a wide range of biological
activities such as regulation of the immune system, generation of acute phase
reactions (43) and also plays a key role in metabolism during exercise (63, 64).
During physical exercise IL-6 is predominantly produced within the working
skeletal muscles (37, 83) and this production can account for the exercise-induced
increase in plasma IL-6 (85).
The effect of IL-6 on biological systems is dependent on the availability of IL-6
receptors (both membrane-bound and soluble forms). Initiation of IL-6 signalling
occurs when IL-6 is bound to the IL-6 receptor and the ubiquitous signal trans-
ducing receptor glycoprotein 130 (gp130) (87) as illustrated in Figure 1. Expres-
sion of the membrane-bound form of the receptor is predominantly limited to
hepatocytes and leucocytes with low expression in resting skeletal muscle (41).
The circulating soluble IL-6 receptor (sIL-6R), in contrast to other soluble
cytokine receptors such as the soluble tumour necrosis factor receptor, has an ago-
nistic effect by further stimulating the biological activity of its ligand (35). sIL-6R
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Figure 1. A schematic representation: A. The membrane-bound IL-6/IL-R/gp130 complex,
consisting of 2 IL-6, 2 IL-6R and 2 gp130 molecules and B. The soluble IL-6/IL-6R complex
in cells lacking the membrane- bound IL-6R. Adapted from (58).
is a 50-55 kDa ligand binding protein derived from the extracellular part of the
gp80 receptor by differential IL-6R mRNA splicing (DS-sIL-6R) or by proteolyt-
ic cleavage (shedding; PC-sIL-6R) of the cognate IL-6R. The two distinct iso-
forms control the overall properties of the soluble receptor, with evidence sug-
gesting that in some tissues IL-6 signalling only occurs when the membrane form
is lysed (91). The predominant sIL-6R isoform in plasma of healthy individuals is
PC-sIL-6R (> 99%) but certain conditions, such as sleep, can influence the iso-
form ratios (15).
The mechanisms regulating plasma sIL-6R concentrations are unclear. sIL-6R is
generated by direct production of an sIL-6R form through translation of alterna-
tively spliced mRNAs or by proteolytic cleavage of membrane molecules. The
predominant isoform of sIL-6R in plasma in healthy individuals is the membrane
anchored proteolytically cleaved form (34). A decrease in plasma sIL-6R might
be a consequence of several mechanisms. Firstly, an increased consumption of
circulating sIL-6R owing to the formation of IL-6/sIL-6R complex in the pres-
ence of IL-6 and subsequent binding and internalization of the complex by effec-
tor cells expressing the gp130 where the complex is degraded may have occurred
(97). Secondly, protein kinase C (PKC) appears to play a role in sIL-6R shedding
and inhibition of PKC appears to have a down-regulating effect on sIL-6R pro-
duction (50). Finally, increased renal clearance of sIL-6R cannot be dismissed.
Very small amounts of sIL-6R in comparison to circulating levels are found in the
urine of healthy individuals at rest (20).
Effect of acute exercise on sIL-6R
In contrast to the abundance of recent research investigating the effect of exercise
on IL-6, relatively little research has been conducted on sIL-6R and exercise;
hence, there are conflicting data on circulating sIL-6R concentrations immediate-
ly after and during recovery from exercise (Table 1).
After acute endurance exercise sIL-6R has been shown not to change (39, 41, 61,
66); although in these studies subject number has been small –around 6. Alterna-
tively increases have been noted and peak levels occur from immediately after
exercise to beyond 6 h after exercise (25, 69) Leggate et al unpublished data,
Loughborough University, UK). The differing peak time points are likely due to
differing exercise regimens and whether the data has been corrected for plasma
volume. A novel finding in our own study (69) was that these levels were signifi-
cantly correlated with fatigue and exercise load.
To date no research has been conducted on the influence of exercise on the sIL-6R
isoform ratio but unpublished data from our laboratories suggest that the ratio is
unaffected by prolonged endurance-type exercise (Walshe et al, Northumbria
University, UK) and that during intermittent high intensity exercise the DS-sIL-
6R component increases significantly (Nimmo, Loughborough University, UK).
The formation of the active binary complex (IL-6/sIL-6R) substantially extends
the plasma half life of IL-6 (65) and mathematical modelling would suggest that
70% of the circulating IL-6 is in this form at rest (21) and that the complex
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increases two fold after endurance exercise (25). However, to prevent an uncon-
trolled generalised stimulation by the IL-6/sIL-6R complex, research indicates
that the soluble form of glycoprotein 130 (sgp130) acts as a natural inhibitor of
the agonistic complex (38).
The role of a recombinant isoform of gp130 as a pharmacological therapy to
reduce IL-6-driven inflammation in rheumatoid arthritis is under investigation
and results indicate that the use of the sgp130 isoform is an effective antagonist of
IL-6 signalling pathways. To date studies report that exercise (eccentric or pro-
longed) has little (27) or no impact on circulating levels of sgp130 (14, 39, 41) in
males (age range 18 – 40 years) although recently elevations in the sgp130 were
reported in sedentary, middle aged men (age 50.6 ± 7.8 years) following a single
bout of fatiguing acute exercise (27) as well as in older men (age 71 ± 2.0 years)
versus younger men both at rest and 6 h after a bout of downhill running (73).
Effect of endurance training on sIL-6R
Endurance training has been shown to decrease resting sIL-6R in patients with
chronic heart failure (1) and in obese subjects who reduce body fat (78, 96). This
reduction in sIL-6R is contrary to the increase occurring in the expression of IL-
6R mRNA in skeletal muscle with a consequent decrease in the response to acute
exercise (39). The possibility may exist that the membrane-bound receptor and
the soluble receptor may work reciprocally (i.e. when the membrane form
increases the circulating levels are able to decrease). This could have significant
implications for the way in which exercise interventions relate to chronic low
grade inflammation.
Metabolic aspects of sIL-6R
A reported metabolic effect of IL-6 signalling is to stimulate lipolysis and fat oxi-
dation (90) in humans at rest and to exert an effect on glucose turnover during
exercise (19). When muscle glycogen is low mRNA expression of IL-6 in skeletal
muscle is enhanced (10, 40, 84) hence, the release of IL-6 from the working mus-
cle is greater and subsequently plasma IL-6 concentrations rise (40, 84). Glucose
ingestion, therefore offsets this increase in IL-6 (18) however IL-6R expression in
skeletal muscle was independent of glycogen availability (39); and we have
shown that although glucose ingestion during a 90-minute time trial run reduced
elevations in IL-6, these changes did not affect performance (70).
The majority of glucose turnover studies have concentrated on the effects of IL-6
without considering IL-6R. Both whole body infusion studies and in vitro studies
have shown contradictory results. The rhIL-6 infusion studies are discussed fully
by Pedersen et al (62). Analysis of the in vitro studies reveals that in cultured
skeletal muscle cells (L6 myotubes) when exposed to IL-6 enhanced basal and
insulin-stimulated glucose uptake at 1ng.ml-1 and 100 ng.ml-1 respectively, (9)
whereas in rodent skeletal muscle, IL-6 (120 ng ml-1) has been demonstrated to
increase basal glucose uptake only in a muscle predominantly composed of Type
2 fibres unless insulin is present (22). In human biopsy, Glund et al (23) were able
to demonstrate that at the same concentration of IL-6 (120 ng ml-1) the action of
insulin was not enhanced, but basal glucose transport was increased. These facts
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taken together with the evidence that glucose turnover has been shown to increase
in response to rhIL-6 infusion during exercise (19) the expression of IL-6R (41)
and sIL-6R increases with exercise (25, 27, 69) suggests that there may be a sig-
nificant role for the receptor. In a recent study therefore (26) we investigated the
combined effects of IL-6 and sIL-6R, at physiological and supraphysiological
concentrations on glucose transport in mouse soleus muscle (previously shown by
Geiger et al (22)) to be unresponsive to IL-6 incubations in the absence of
insulin). In this study, we were able to demonstrate that the combined administra-
tion of IL-6 and sIL-6R increases basal glucose transport whilst having no effect
on the action of insulin stimulated glucose uptake.
In agreement with other studies on IL-6 signalling (2, 42), the elevation in glucose
transport at supraphysiological doses (120 ng.ml-1) was also associated with an
increase in phosphorylation of AMPK which, amongst its various roles, can stim-
ulate glucose transport (47, 51). Whilst the increase in glucose transport at supra-
physiological concentrations of IL-6 may have resulted from in an increase in
phosphorylation of AMPK, glucose transport was, however, increased by 125%
whereas AMPK phosphorylation was increased by 90%, suggesting that another
signalling pathway may be involved. In further support of this assertion, at physi-
ological concentrations of IL-6 and sIL-6R glucose transport was increased with
no appreciable changes in total or phosphorylated AMPK (26).
An alternative pathway which has been shown previously to be activated by IL-6
and its receptor system is the phosphorylation of PKB/Akt (93). Protein kinase
B/Akt is well known for its role in insulin but not contraction-mediated stimula-
tion of skeletal muscle glucose transport through glucose transporter isoform 4
(GLUT4) translocation (6). Neither Glund et al. (23) nor Gray et al. (26) were
able to identify any changes in the phosphorylation of PKB/Akt. Using the L6
myotube model Carey et al. (9) demonstrated that signalling through the IL-6/IL-
6R/gp130 receptor, resulted in STAT3 phosphorylation after 10 minutes whilst
SOCS3 increased after 60 minutes. Insulin affected neither of these proteins.
Alongside the well-established link between IL-6 and AMPK, this supports the
notion that the role of IL-6 in mediating glucose transport is independent of
insulin. (Figure 2).
sIL-6R and fatigue in disease and exercise
IL-6 can cross the blood-brain barrier (3) and IL-6 receptors exist at numerous
sites in the brain (75) raising the intriguing possibility that IL-6 released at the
muscle can initiate signalling in the brain. Increased levels of sIL-6R have also
been demonstrated to increase the responsivity of the brain to IL-6 (76) and cause
a greater suppression of locomotor activity and general sickness behaviour above
that of raised IL-6 levels alone (74).
Clinical research indicates that IL-6 levels are positively related to the degree of
fatigue experienced in certain conditions, for example, Castleman’s disease (55),
primary biliary cirrhosis (94) and terminal cancer (33). Patients reporting exces-
sive fatigue had significantly higher levels of IL-6 than those who were non-
fatigued (32, 94). Exogenous peripheral administration of IL-6 has been associat-
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ed with increased feelings of fatigue and reduced ability to concentrate (82) as
well as impaired athletic performance in trained athletes (72) suggesting that sys-
temically elevated IL-6 can induce a centrally-mediated effect.
Previous theories have suggested that elevated IL-6 levels may play a role in the
debilitating fatigue reported by some athletes undergoing excessive exercise load-
ing (67, 79) but to date research has not supported this conjecture (28, 59, 69, 71).
However, Robson postulated that whilst athletes with excessive fatigue may not
exhibit IL-6 values above the norm they may exhibit an increased sensitivity to
IL-6 which could possibly occur as a consequence of elevated levels of the sIL-
6R. Indeed, in the clinical setting, a positive relationship between sIL-6R and
fatigue has been reported: breast cancer survivors with persistent fatigue had sig-
nificantly elevated sIL-6R levels compared to non fatigued survivors but IL-6 lev-
els were not different between groups (12). A similar finding for IL-6 was report-
ed in individuals with chronic fatigue syndrome compared to healthy matched
controls although in this study there was no difference in IL-6R (60). Interesting-
ly, when the sIL-6R receptor signalling is blocked by anti-IL-6 receptor antibody
therapy in conditions such as Castleman’s disease, which is characterised by an
overproduction of IL-6 and debilitating fatigue, fatigue was significantly attenuat-
ed (55). A similar finding has also been reported in rheumatoid arthritis patients
following such treatment (54).
In the exercise setting, a positive relationship has also been reported between sIL-
6R and fatigue: we demonstrated that sIL-6R concentrations were significantly
elevated in individuals completing a 6-day endurance mountain bike event (468
km in 6 days) where sIL-6R concentrations were positively correlated with daily
fatigue scores (69). To date, no studies have reported any interventions that can
reduce the sIL-6R response to exercise. Whilst carbohydrate ingestion can signif-
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Figure 2. Schematic diagram of IL-6/IL-6R/gp130 signalling mechanism
icantly attenuate the rise in circulating IL-6 concentrations during prolonged exer-
cise (5, 52, 70), we have found that carbohydrate ingestion during prolonged exer-
cise (>2 h) had no effect on plasma sIL-6R up to 24 h post-endurance exercise
(92).
The effect of exercise induced muscle damage on sIL-6R
To date, little is known about the effect of eccentric exercise on plasma concentra-
tions of sIL-6R or sgp130 or their relationship with DOMS and muscle function.
Activities involving unaccustomed eccentric muscle actions result in exercise-
induced muscle damage (EIMD) (8, 77, 88). EIMD is associated with a variety of
consequential effects such as structural damage of the sarcomeres, protein leak-
age from damaged myofibres (81), loss of muscle force (8, 29, 88), delayed onset
of muscle soreness (DOMS) (46, 56, 77), and an acute but low grade inflammato-
ry response (46, 48). Indeed, elevations in circulating, IL-6, have been correlated
with magnitude of DOMS and rises in circulating myosin heavy chain fragments
(a marker of disruption within the muscle fibre contractile unit) following eccen-
tric exercise suggesting a relationship between soreness, damage and inflamma-
tion (46).
One study has investigated the effect of maximal eccentric contractions (using
elbow flexors) on plasma sIL-6R concentration and reported an increase at 4 h
and 8 h post-exercise but levels returned to baseline levels by 12 h (14). Following
a bout of downhill running in a healthy young and older men, sIL-6R concentra-
tions were unaltered by exercise (at 6 h and 24 h post-exercise) although levels
were significantly higher in the older participants (73). Neither study reported
relationships between inflammatory mediators and other indicators of EIMD.
Considering there is substantial evidence that both IL-6 and sIL-6R play a role in
fatigue (27, 69, 72), nociception and inflammatory hyperalgesia (reviewed else-
where (13, 80)), it is surprising that only a few studies have investigated the rela-
tionship between IL-6 and indices of EIMD. To date, no studies have investigated
changes in sIL-6R or sgp130 beyond 24 h into recovery nor their relationship with
DOMS or muscle function.
The purpose of this study was to examine the relationship between sIL-6R,
sgp130 and recovery from eccentric exercise up to 72 h. It is our intention that the
findings from this study will help to further our understanding of the relationship
between inflammatory mediators and indicators of exercise-induced muscle dam-
age.
MATERIALSAND METHODS
Participants
Eighteen healthy recreationally trained males (age 21 ± 3 y; height 182 ± 7.4 cm;
mass 78.8 ± 10.3 kg) volunteered to take part in the study. None had been unwell
or taken medication in the preceding two weeks. All subjects were informed of
experimental procedures and gave their written informed consent to participate in
the study. Institutional ethical approval was obtained and all procedures were con-
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ducted according to the Declaration of Helsinki. Subjects were instructed to arrive
at the laboratory in a fasted state, having avoided physical activity for at least 48 h
and not taken any nutritional supplements, caffeine, alcohol or anti-inflammatory
drugs. All subjects were tested at approximately the same time of day to minimise
diurnal variation.
Procedures
Design
All subjects were required to attend the laboratory on 4 consecutive days. Day 1
baseline blood samples were collected prior to any exercise testing and before
subjects had broken their overnight fast. On all subsequent days early morning
venous blood samples were obtained from subjects following an overnight fast.
Following this, subjects rated their level of muscle soreness on a visual analogue
scale, completed a standardised warm-up and carried out isokinetic muscle per-
formance measures. On day 1, after completion of pre-testing baseline measure-
ments, all participants completed a bout of exercise designed to induce acute mus-
cle damage.
Muscle-damaging exercise
Muscle damage was induced in the hamstrings. Participants completed 6 sets of
10 repetitions of unilateral eccentric/concentric actions of the knee flexors at a
test speed of 1.05 rad/s using a Cybex Isokinetic Dynamometer (Cybex Norm,
Cybex International, New York). Participants were instructed to provide a maxi-
mal effort during the eccentric phase of each leg flexion and return their leg to the
starting position during the concentric phase. This protocol has previously been
shown to induce muscle damage (11).
DOMS measurement
The degree of DOMS experienced was measured on a visual analogue scale. Par-
ticipants were required to rate the level of soreness, combined for both legs, that
they perceived to have in their hamstrings when standing from 0 (no
pain/soreness) up to 10 (pain/soreness as bad as it could be).
Measures of isokinetic muscle performance
Peak torque of the best attempt in a repetition of a set of 6 concentric maximal-
effort knee flexion actions was measured on the dominant leg at a test speed of
1.05 rad/s using a Cybex Isokinetic Dynamometer (Cybex Norm, Cybex Interna-
tional, NewYork).
Blood sample collection and analysis
Venous blood was collected into appropriate vacutainer tubes (Becton Dickinson,
Swindon, UK) and centrifuged at 1500 g for 10 min. The supernatant was aspirat-
ed and immediately frozen at –80ºC until later analysis.
Plasma IL-6, sIL-6R, sgp130 concentrations were analysed from K3EDTA treated
venous blood using an enzyme linked immunosorbent assay (R&D Systems, Min-
neapolis, USA). Intra- and inter-assay coefficient of variations for IL-6 were less
than 2% and 6%, respectively; sIL-6R were 7% and 6%, respectively and sgp130
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were 5% and 6%, respectively. High sensitivity plasma C-reactive protein (CRP)
analysis and creatine kinase (CK) activity was performed on the Siemens Medical
solutions Advia 2400, UK with intra- and inter-assay coefficient of variations of
less than 5.8% and 6.6%, respectively and 1.1% and 2.2%, respectively.
Data Analysis
Data in the figures and tables are presented as mean values and standard error of
the mean. Statistical evaluation of the results was carried out using repeated meas-
ures analysis of variance with post-hoc Tukey tests where applicable. Relation-
ships between variables were analyzed using Pearson’s product moment correla-
tions. The accepted level of significance was p ≤0.05.
RESULTS
Evidence of Muscle Damage
For all subjects the protocol was deemed to have caused EIMD in both legs. This
was evident from reductions in isokinetic muscle performance and increases in
CK and DOMS over the 3 days post-eccentric exercise.
Isokinetic muscle performance
Peak torque of the dominant leg was significantly reduced by 48 h post-exercise
but returned to baseline levels by 72 h (Table 2).
DOMS
Ratings of perceived muscle soreness were significantly higher than baseline at
24 h and 48 h post-eccentric exercise (p<0.05). DOMS was inversely correlated
with peak muscle torque at 48 h post-exercise (r = -0.50; p<0.05) (Table 2).
Blood-borne markers
Plasma CK activity was significantly elevated during recovery at all post-exercise
time points (p <0.05) (Table 2). CRP, IL-6 and sgp130 concentrations remained
unaltered for the duration of the trial whereas sIL-6R was significantly reduced at
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Table 2.  The effect of muscle damaging exercise on mechanical and biochemical 
parameters. 
 
Baseline 
pre-exercise  
24 h post-
exercise 
48 h post-
exercise 
72 h post-
exercise 
Delayed onset of 
muscle soreness 
 
0.3 ± 0.1 
 
3.1 ± 0.5* 
 
4.7 ± 0.5* 
 
3.2 ± 0.5* 
Peak Torque (Nm) 
 
137 ± 8 124 ± 8 120 ± 8* 122 ± 8 
Creatine Kinase 
activity (U.l
-1
)
319 ± 192 1485 ± 772* 7966 ± 3116*
 
15143 ± 5504*
 
C-reactive protein 
(mg.ml
-1
)
2.7 ± 0.4 2.6 ± 0.4 2.7 ± 0.4 3.8 ± 0.6
 
*significantly different from baseline (p<0.05) 
48 h and 72 h post-exercise (p<0.05)
compared to baseline measures (Fig-
ures 3-5). Peak torque and sIL-6R at
24 h and 48 h were negatively corre-
lated (r = -0.42, p<0.05; r = -0.57;
p<0.01, respectively). DOMS and
sIL-6R at 48 h were positively corre-
lated at 48 h (r = 0.45; p<0.05).
DISCUSSION
The novel finding from our study
was that sIL-6R concentrations were
reduced for 72 h following a single
bout of eccentric exercise which
induced muscle injury. Furthermore,
significant relationships were found
between sIL-6R, peak muscle torque
and DOMS during the recovery peri-
od.
In contrast to these findings, we
have previously demonstrated that
sIL-6R concentrations are elevated
the morning (~16 h post-exercise)
after prolonged cycling exercise
which we postulated may have
occurred as a consequence of
increased CRP and IL-6 concentra-
tions (69). In vitro elevations in CRP
within physiological ranges can
induce shedding of sIL-6R from
neutrophils (36) and hepatocyte
CRP production is increased in the
presence of IL-6 (44). However, we
found no significant increase in IL-6
or CRP during recovery from
EIMD. Although eccentric exercise
causes greater local muscle damage
than prolonged endurance exercise, alterations in plasma cytokine levels and CRP
appear to be smaller (7, 69, 86). During endurance exercise a host of factors aside
from muscle damage which are known inflammatory stimuli such as energy cri-
sis, oxidative stress, endotoxaemia due to gut ischemia, metabolic and hormonal
alterations may contribute to the increase in inflammatory mediators. A single
bout of eccentric exercise takes a relatively short period of time, involves activa-
tion of isolated small muscle groups compared to cycling or running and is
unlikely to induce an energy crisis or endotoxaemia (although some oxidative
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Figure 3. The effect of muscle damaging exercise on
plasma IL-6 concentration (n=18).
Figure 4. The effect of muscle damaging exercise on
plasma sIL-6R concentration (n=18).
*significantly lower than baseline (p<0.05).
Figure 5. The effect of muscle damaging exercise on
plasma sgp130 concentration (n=18).
damage may occur as a consequence of neutrophil infiltration (4)). It is, therefore,
perhaps unsurprising that a lower or insignificant IL-6 response is triggered fol-
lowing the current protocol.
Elevated sIL-6R concentrations are also reported during infectious episodes and in
a variety of inflammatory conditions such as rheumatoid arthritis (53), asthma (95)
and Castleman’s diease (55). However, there are a few clinical conditions where
sIL-6R levels are reduced. In stroke patients (16) and following a myocardial
infarction (89) sIL-6R is lowered during recovery. Both of these conditions gener-
ally involve a single inflammatory event and the downregulation of sIL-6R may be
part of a regulatory response attenuating an acute inflammatory response (17).
During an acute inflammatory event such as EIMD, leukocyte recruitment is char-
acterised by an initial infiltration of neutrophils and then replaced by a more sus-
tained influx of monocytes approximately 24 – 48 h post-injury (30, 45). Hurst et
al (31) have demonstrated that IL-6 and sIL-6R play a role in controlling the pat-
tern of leukocyte recruitment during an acute inflammatory episode. They deter-
mined that infiltrating neutrophils shed sIL-6R from their cell surface which regu-
late neutrophil–activating chemokines (Modur et al (49) suggest that the limiting
factor for IL-6 signalling from neutrophils to endothelial cells is sIL-6R, not the
cytokine IL-6). This in turn contributes to the suppression of neutrophil recruit-
ment and the concurrent attraction of monocytes. Thus sIL-6R plays an active role
in the trafficking of leukocytes.
During short-term recovery from eccentric exercise, studies have reported eleva-
tions in sIL-6R levels at 4 and 8 h post-exercise with levels returning to baseline
at 12 h (14) and remaining at baseline at 24 h (73). In this study we found no
change in sIL-6R levels at 24 h (in agreement with Sacheck et al (73)) but that
levels were significantly reduced during longer term recovery at 48 h and 72 h
post-exercise. We propose that this biphasic pattern in sIL-6R concentration post-
EIMD reflects changes in leukocyte sub-population migration into affected tissue.
When sIL-6R levels are elevated in the initial period following EIMD this reflects
signalling suppressing the neutrophil infiltration into the damaged area and
increasing monocyte/macrophage infiltration. When sIL-6R levels are lowered
during the later stage of recovery from EIMD, this may indicate the regenerative
phase when macrophage infiltration into the affected tissue is suppressed and tis-
sue repair and remodelling occurs.
Although we report a mean reduction in sIL-6R concentrations during recovery
from EIMD at 48 h and 72 h, a relationship was found between sIL-6R, peak
muscle torque and DOMS. Our data suggests that higher levels of sIL-6R may
partly contribute to the concurrent reduction in peak muscle strength and increase
in perceived muscle soreness (48 h only). Some of the reduction in peak muscle
torque may be due to soreness in the recruited muscles inhibiting the production
of a maximal effort by subjects as a negative relationship was also found between
soreness scores and peak torque. The positive relationship between DOMS sore-
ness score and sIL-6R suggests the soluble receptor may be involved in percep-
tion of pain following EIMD. There is considerable evidence that IL-6 plays a
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role in nociception and inflammatory hyperalgesia (comprehensively reviewed
elsewhere (13, 80)) and that IL-6 in combination with sIL-6R may have a greater
sensitising effect than IL-6 alone (57). Indeed, neutralizing the IL-6 signalling
pathway can abolish the sIL-6R-mediated sensitising effect and reduce the per-
ception of pain following heat injury in rats (57), this has yet to be demonstrated
in humans following EIMD.
In conclusion, our finding that sIL-6R concentrations are decreased 2 - 3 days fol-
lowing a single bout of EIMD may reflect a regulatory mechanism controlling the
influx of different leukocyte subpopulations into damaged tissue. Our data sug-
gests an association between sIL-6R, perception of pain and reduced peak muscle
performance post-EIMD but further investigation is warranted to explore this
relationship.
Summary and future directions
In summary, we believe there is a significant case to consider the IL-6R in exer-
cise studies. These studies could focus on the role of sIL-6R on human skeletal
muscle at physiological levels, the relationship between muscle soreness and
power production with sIL-6R, clarification of the signalling mechanism associat-
ed with short term and long term exposure to IL-6 and the role of receptor in
insulin resistance.
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